Alerts

Peps and Kurlon battle out over ‘No Turn”

RNA IP  Comments (0)
Should a prior used mark though used intermittently be given higher threshold and protection than registered mark? The two companies in mattress trade are loggerheads over use of the mark NO TURN. The Plaintiff, Peps...

Fourth factor in Pharma patent infringement cases

RNA IP  Comments (0)
This post analyses the weightage of fourth factor that is ‘public interest’ in granting interim injunction in the pharmaceutical cases in light of an ex parte interim injunction granted in Novartis Ag & Anr vs...

Articles

Peps and Kurlon battle out over ‘No Turn”

RNA IP  Comments (0)
Should a prior used mark though used intermittently be given higher threshold and protection than registered mark? The two companies in mattress trade are loggerheads over use of the mark NO TURN. The Plaintiff, Peps...

Fourth factor in Pharma patent infringement cases

RNA IP  Comments (0)
This post analyses the weightage of fourth factor that is ‘public interest’ in granting interim injunction in the pharmaceutical cases in light of an ex parte interim injunction granted in Novartis Ag & Anr vs...

Newsletters

Peps and Kurlon battle out over ‘No Turn”

RNA IP  Comments (0)
Should a prior used mark though used intermittently be given higher threshold and protection than registered mark? The two companies in mattress trade are loggerheads over use of the mark NO TURN. The Plaintiff, Peps...

Fourth factor in Pharma patent infringement cases

RNA IP  Comments (0)
This post analyses the weightage of fourth factor that is ‘public interest’ in granting interim injunction in the pharmaceutical cases in light of an ex parte interim injunction granted in Novartis Ag & Anr vs...

F.A.Q.

Peps and Kurlon battle out over ‘No Turn”

RNA IP  Comments (0)
Should a prior used mark though used intermittently be given higher threshold and protection than registered mark? The two companies in mattress trade are loggerheads over use of the mark NO TURN. The Plaintiff, Peps...

Fourth factor in Pharma patent infringement cases

RNA IP  Comments (0)
This post analyses the weightage of fourth factor that is ‘public interest’ in granting interim injunction in the pharmaceutical cases in light of an ex parte interim injunction granted in Novartis Ag & Anr vs...